In an ever-evolving clinical landscape, staying at the forefront of the latest trends and innovations is a strategic advantage. The high incidence and prevalence rates of breast cancer, coupled with increases in R&D investment and advancements in cancer biology and pharmacology, point towards an imminent rise in the demand for efficient breast cancer therapies. To maximize the opportunities presented by these developments in the global breast cancer therapy market, a comprehensive market research report detailing the present and future dynamics of this demanding landscape is crucial.
The report provides insights into the current challenges and prospects in the breast cancer therapy market, including the effects of ongoing innovations and separate collaborations by market leaders aimed at drug development. Understanding these factors, along with potential growth areas such as the chemotherapy segment and geographical focuses like North America, could present significant growth opportunities for your organization. Providing data-driven insights, the report helps you to stay ahead in the market, making critical strategic decisions that drive your organization towards achieving its business goals.
Following the outbreak of COVID-19, the market faced a slight setback owing to delays in diagnoses, shortages of drugs, and unavailability of healthcare professionals. As per a research study published in October 2021 by the Journal of Medical Screening, during the COVID-19 pandemic, breast cancer screening and participation were affected globally, and as per the same source, in response to COVID-19, many countries halted their breast screening programs. For instance, national screening programs were suspended in Canada, the Netherlands, Germany, Italy, the UK, and Australia, for 1-6 months in 2020. Thus, the COVID-19 pandemic impacted the market studied. Although, with the ongoing vaccinations and stabilizing cases of COVID-19, the market studied is expected to regain its full potential over the forecast period.
The major factors fueling the market's growth are the high incidence and prevalence rates of breast cancer, increasing investment in research and development, and advancements in cancer biology and pharmacology, promoting drug development.
According to Globocan, in 2020, about 2,261,419 new cancer cases were reported worldwide, contributing to about 11.7% of the total cancer cases. As per canceraustralia.gov.au, in 2021, 20,030 new breast cancer cases were diagnosed in the country (164 males and 19,866 females). The same source reports that in 2021, a person had an estimated 1 in 15 (or 6.7%) risk of being diagnosed with breast cancer by the age of 85 (1 in 8 or 13% for females and 1 in 829 or 0.12% for males). Therefore, the high burden of breast cancer is increasing the demand for breast cancer treatment, thereby contributing to the market's growth.
The increasing focus of research studies by the market players. For instance, in September 2021, Novartis AS collaborated with Solti on HARMONIA, an international, randomized, Phase III, multicenter, and open-label study of Kisqali (ribociclib) versus Ibrance (palbociclib), both in combination with endocrine therapy. This study was on patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer with a HER2-enriched (HER2E) intrinsic subtype.
Increasing launches by manufacturers to meet the growing demand for innovative products are expected to drive market growth. For instance, in July 2021, Arvinas Inc. and Pfizer Inc. collaborated to develop and commercialize ARV-471, an investigational oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. Such factors potentially drive the demand for the adoption of breast cancer therapy worldwide.
On the other hand, the risk of adverse effects of radiation exposure and stringent regulatory scenarios are hindering the market's growth.
Breast Cancer Therapy Market Trends
Chemotherapy Segment Expected to Witness High Growth Over the Forecast PeriodChemotherapy is the most common form of therapy used to stop or slow down the growth of cancerous cells. It is the most common treatment for triple-negative breast cancer patients.
According to the CDC, in a November 2021 update, nearly 650,000 cancer patients (including breast cancer patients) receive chemotherapy every year in the United States. Thus, the growing number of patients receiving chemotherapy and the development of new products are expected to significantly contribute to the market's growth.
Furthermore, the number of product launches in this segment is expected to drive its growth. For instance, in July 2021, Merck, also known as MSD outside the United States and Canada, announced that the United States Food and Drug Administration (FDA) approved KEYTRUDA, Merck’s anti-PD-1 therapy, for the treatment of patients with high-risk early-stage triple-negative breast cancer (TNBC). Based on Phase III KEYNOTE-522 trial, this is meant to be used in combination with chemotherapy as a neoadjuvant treatment and then continued as a single agent as adjuvant treatment after surgery. Also, in May 2021, Zydus Cadila launched a next-generation breast cancer drug in India. The drug, Trastuzumab emtasine, is considered the first targeted chemotherapy drug for breast cancer.
Thus, owing to the abovementioned factors, the market segment is expected to show growth over the forecast period.
North America Expected to Dominate the Market Over the Forecast PeriodWithin North America, the United States is expected to dominate the overall market throughout the forecast period. The major factors fueling the market's growth are the increasing burden of breast cancer in the country, growing awareness about breast cancer, and increasing product launches.
In the United States, breast cancer is one of the leading cancer types. According to the January 2022 update by breastcancer.org, around 1 in 8 women in the country (about 13%) develop invasive breast cancer over their lifetime. The same source reports that, in 2022, an estimated 287,850 new cases of invasive breast cancer are expected to be diagnosed in women in the United States, as well as 51,400 new cases of non-invasive (in situ) breast cancer. As per the same source, about 2,710 new cases of invasive breast cancer are expected to be diagnosed in men in 2022. A man’s lifetime risk of breast cancer is about 1 in 833.
Furthermore, as per an October 2021 update by the University of North Carolina's School of Medicine, Susan G. Komen, the world’s leading breast cancer organization, announced that it would award USD 1.5 million for three new research projects that examine three unique areas focused on metastatic breast cancer (MBC).
In April 2021, Gilead Sciences Inc. reported that the US FDA granted full approval to Trodelvy (sacituzumab govitecan-hziy) for adult patients with unresectable locally advanced or metastatic TNBC who have received two or more prior systemic therapies, at least one of them for metastatic disease. Thus the increased product approval from the US FDA is expected to boost the growth of the market over the forecast period.
Thus, due to the above-mentioned factors, the market in North America is expected to grow during the forecast period.
Breast Cancer Therapy Market Competitor AnalysisThe breast cancer therapy market is competitive and consists of several major and small players. Some of the major players in the market are Novartis AG, Pfizer Inc., F. Hoffmann-La Roche, Eisai Co. Ltd., and Merck & Co. Inc.
Additional benefits of purchasing the report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1.2 Scope of the Study
4.2 Market Drivers
4.2.1 High Incidence and Prevalence Rate of Breast Cancer
4.2.2 Increasing Investments in R&D
4.2.3 Advancements in Cancer Biology and Pharmacology, Promoting Drug Development
4.3 Market Restraints
4.3.1 Risk of Adverse Effects of Radiation Exposure
4.3.2 Stringent Regulatory Scenarios
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1.1 Radiation Therapy
5.1.2 Targeted Therapy
22.214.171.124 Tykerb (Lapatinib)
126.96.36.199 Other Targeted Therapies
5.1.3 Hormonal Therapy
188.8.131.52 Selective Estrogen - Receptor Modulators
184.108.40.206 Aromatase Inhibitors
220.127.116.11 Other Hormonal Therapies
18.104.22.168 Alkylating Agents
5.2.1 North America
22.214.171.124 United States
126.96.36.199 United Kingdom
188.8.131.52 Rest of Europe
184.108.40.206 South Korea
220.127.116.11 Rest of Asia-Pacific
5.2.4 Middle East and Africa
18.104.22.168 South Africa
22.214.171.124 Rest of Middle East and Africa
5.2.5 South America
126.96.36.199 Rest of South America
6.1.1 AstraZeneca PLC
6.1.2 Bristol-Myers Squibb Company
6.1.3 Eisai Co. Ltd
6.1.4 Eli Lilly and Company
6.1.6 GlaxoSmithKline PLC
6.1.7 Halozyme Inc.
6.1.8 Novartis AG
6.1.9 Pfizer Inc.
6.1.10 Hikma Pharmaceuticals
6.1.11 Baxter Healthcare Corporation
6.1.12 FRESENIUS KABI
6.1.13 Teva Pharmaceutical Industries Ltd
6.1.14 Celltrion Healthcare
6.1.15 Viatris Inc.
A selection of companies mentioned in this report includes:
- AstraZeneca PLC
- Bristol-Myers Squibb Company
- Eisai Co. Ltd
- Eli Lilly and Company
- GlaxoSmithKline PLC
- Halozyme Inc.
- Novartis AG
- Pfizer Inc.
- Hikma Pharmaceuticals
- Baxter Healthcare Corporation
- FRESENIUS KABI
- Teva Pharmaceutical Industries Ltd
- Celltrion Healthcare
- Viatris Inc.